Brokers Offer Predictions for VERV FY2025 Earnings

Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Verve Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski expects that the company will earn ($2.67) per share for the year. The consensus estimate for Verve Therapeutics' current full-year earnings is ($2.49) per share.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.11. The company had revenue of $6.87 million for the quarter, compared to analysts' expectations of $2.75 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The firm's quarterly revenue was up 120.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.72) EPS.

VERV has been the topic of a number of other reports. Royal Bank of Canada lowered their price target on shares of Verve Therapeutics from $20.00 to $17.00 and set an "outperform" rating on the stock in a research note on Wednesday, November 6th. Canaccord Genuity Group raised their price target on Verve Therapeutics from $29.00 to $32.00 and gave the company a "buy" rating in a research report on Wednesday, November 6th. Finally, HC Wainwright lowered their target price on Verve Therapeutics from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, November 6th.

Verve Therapeutics Stock Up 2.5 %

VERV stock traded up $0.20 on Wednesday, reaching $8.00. 2,860,631 shares of the company's stock were exchanged, compared to its average volume of 1,776,244. The stock has a fifty day moving average of $5.84 and a 200-day moving average of $5.79. The firm has a market cap of $676.86 million, a PE ratio of -3.29 and a beta of 1.68. Verve Therapeutics has a twelve month low of $4.30 and a twelve month high of $19.34.

Hedge Funds Weigh In On Verve Therapeutics

A number of hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC grew its stake in shares of Verve Therapeutics by 189.7% in the fourth quarter. GAMMA Investing LLC now owns 6,054 shares of the company's stock valued at $34,000 after buying an additional 3,964 shares in the last quarter. Creative Planning acquired a new stake in Verve Therapeutics in the third quarter valued at approximately $50,000. PFG Investments LLC purchased a new stake in shares of Verve Therapeutics during the third quarter valued at approximately $53,000. Erste Asset Management GmbH acquired a new stake in shares of Verve Therapeutics during the third quarter valued at about $56,000. Finally, Impact Partnership Wealth LLC acquired a new stake in Verve Therapeutics during the 4th quarter valued at approximately $70,000. Hedge funds and other institutional investors own 97.11% of the company's stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.